These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22164689)

  • 21. [Pharmaceuticals and Medical Devices Agency (PMDA)'s new action for Pharmaceutical Affairs Consultation on Research and Development (R&D) Strategy].
    Masuyama K
    Yakugaku Zasshi; 2013; 133(2):183-6. PubMed ID: 23370511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Technical implications on the quality standard of new drugs].
    Uchiyama M
    Eisei Shikenjo Hokoku; 1995; (113):135-6. PubMed ID: 8717247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [In order to perform clinical trials efficiently in Japan--important issues regarding monitoring by sponsors].
    Kaichi S; Oda T; Goto K; Sato K
    Nihon Kokyuki Gakkai Zasshi; 2007 Nov; 45(11):829-35. PubMed ID: 18051783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accelerating Regulatory Science Initiatives for the Development of Drugs for Alzheimer's Disease in Japan.
    Moritoyo T
    Clin Ther; 2015 Aug; 37(8):1622-6. PubMed ID: 26342202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. History of healthcare technology assessment in Japan.
    Hisashige A
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():210-8. PubMed ID: 19527539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The MIHARI project: establishing a new framework for pharmacoepidemiological drug safety assessments by the Pharmaceuticals and Medical Devices Agency of Japan.
    Ishiguro C; Takeuchi Y; Uyama Y; Tawaragi T
    Pharmacoepidemiol Drug Saf; 2016 Jul; 25(7):854-9. PubMed ID: 27222073
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical pharmacologists and drug regulation--future perspective in Japan.
    Hirokawa K
    Br J Clin Pharmacol; 1996 Jul; 42(1):63-71. PubMed ID: 8807146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Development of an anticancer drug in Japan based on a new clinical trial system].
    Nakashima H; Nakano S
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):287-94. PubMed ID: 9492818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trends and events in FDA regulation of medical devices over the last fifty years.
    Munsey RR
    Food Drug Law J; 1995; 50 Spec():163-77. PubMed ID: 10343041
    [No Abstract]   [Full Text] [Related]  

  • 32. Reforms of regulatory pathways for approval of new antineoplastic drugs in Japan from 2004 to 2019 and accompanying changes in pivotal clinical trial designs.
    Hirai T; Suzuki A; Yamori T; Matsuura M
    Invest New Drugs; 2022 Feb; 40(1):142-150. PubMed ID: 34417913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Current PMDA Activities for Use of Biomarkers in Drug Evaluation].
    Ishiguro A
    Yakugaku Zasshi; 2015; 135(5):681-4. PubMed ID: 25948301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Government regulations and the use of drugs.
    Hafkenschiel JH
    Calif Med; 1967 Aug; 107(2):159-63. PubMed ID: 4862066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A historical review on International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) and internationalization of Japan's new drugs development and regulation].
    Kurokawa T
    Yakushigaku Zasshi; 2014; 49(2):165-70. PubMed ID: 25799837
    [No Abstract]   [Full Text] [Related]  

  • 36. Primer on medical device regulation. Part I. History and background.
    Monsein LH
    Radiology; 1997 Oct; 205(1):1-9. PubMed ID: 9314952
    [No Abstract]   [Full Text] [Related]  

  • 37. The role of the Pharmaceuticals and Medical Devices Agency and healthcare professionals in post-marketing safety.
    Mori K; Watanabe M; Horiuchi N; Tamura A; Kutsumi H
    Clin J Gastroenterol; 2014 Apr; 7(2):103-7. PubMed ID: 26183623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacovigilance of Regenerative Medicine Under the Amended Pharmaceutical Affairs Act in Japan.
    Inokuma Y
    Drug Saf; 2017 Jun; 40(6):475-482. PubMed ID: 28299610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulatory advice and drug development--a case study in negotiating with regulators.
    Seldrup J
    Stat Med; 2011 Jun; 30(13):1628-35. PubMed ID: 21365671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of Generic Drugs in Japan: the Current Situation and Future Prospects.
    Kuribayashi R; Matsuhama M; Mikami K
    AAPS J; 2015 Sep; 17(5):1312-6. PubMed ID: 25943503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.